While measurement of interferon chemokines and reports of unwanted side effects of IFN-α therapy were fundamental in establishing a role for type I interferons in patients with SLE, there are practical challenges associated with quantifying IFN-α protein, which is often present at very low concentrations. Here, IFNA1 is linked to systemic lupus erythematosus.